Chronic hepatitis B virus infection is an important cause of morbidity and mortality. Tenofovir disoproxil fumarate and entecavir were licensed for the treatment of hepatitis B virus infection. In this study, the investigators will try to make comparison between Entecavir and Tenofovir and investigate the efficacy.

Inclusion Criteria:

• 18 < Age < 70
• HBV DNA > 100,000 copies/mL and increased ALT over 2 times compared with normal range if HBsAg (+), HBeAg (+)
• HBV DNA > 10,000 copies/mL and increased ALT compared with normal range if HBsAg (+), HBeAg (-)

Exclusion Criteria:

• With HCV or other liver disease
• With kidney disease
• decompensated liver cirrhosis
• with hepatocellular carcinoma
• refuse this clinical trials

treatment of nucleos(t)ide-naive patients who were diagnosed with chronic hepatitis B in Korea